Pancreatic Adenocarcinoma

Epidemiology & Risk Factors - Silent Pancreas Peril

• Incidence: ~10-12 cases per 100,000 annually; high mortality.
• Age: Predominantly >60 years (peak 70-80). Sex: Slight male predilection (M:F ~1.3:1).
• Key Risk Factors:
  • Cigarette smoking (doubles risk; RR ~2-3x)
  • Chronic pancreatitis (RR 5-15x)
  • Diabetes Mellitus (long-standing, >5 yrs)
  • Obesity (BMI >30 $kg/m^2$)
  • Family history (1st-degree relative)
  • Inherited genetic syndromes (e.g., BRCA1/2, Peutz-Jeghers)

⭐ Smoking is the most significant, modifiable risk factor, accounting for ~25% of cases.

Pathogenesis & Genetics - Genes Gone Wild

• Precursors: PanIN (Pancreatic Intraepithelial Neoplasia, commonest, graded 1-3), IPMN, MCN.
• Key Mutations (sequential accumulation):
  • KRAS: >90% (oncogene, earliest).
  • CDKN2A (p16): ~90% (tumor suppressor).
  • TP53: ~70-75% (tumor suppressor).
  • SMAD4 (DPC4): ~50-55% (tumor suppressor, ↑metastasis).
  • 📌 Mnemonic: "King Charles Plays Solo" (KRAS, CDKN2A, TP53, SMAD4).
• Hereditary Risk: BRCA1/2, PALB2, Peutz-Jeghers, Lynch, PRSS1.

⭐ SMAD4 loss: late event, specific, linked to poor prognosis & widespread metastasis.

Clinical Features - Telltale Pancreas Pains

• Pain (Head/Body):
  • Epigastric, dull, boring; often radiates to the back.
  • Typically worse at night and when supine; relieved by leaning forward.
• Painless Jaundice: 📌 Courvoisier's Law (palpable, non-tender gallbladder + jaundice suggests malignancy, not stones).
• Weight Loss: Significant, progressive, often with anorexia.
• Migratory Thrombophlebitis: 📌 Trousseau's sign.
• New-onset Diabetes Mellitus (DM), especially in those >50 years.

⭐ New-onset DM in patients >50 years can be an early manifestation of pancreatic cancer, sometimes preceding diagnosis by months to years.

Diagnosis & Staging - Spotting the Shadow

• Presentation: Painless jaundice (head), epigastric pain radiating to back, weight loss. Courvoisier's sign (palpable, non-tender GB).
• Tumor Marker: CA 19-9 ↑ (e.g., >37 U/mL; very high, >1000 U/mL, suggests unresectability/mets). Not for screening.
• Imaging: Multiphase CECT (pancreatic protocol) is key: shows hypodense mass, "double duct sign", vascular involvement, metastases.
  • 
• EUS: Best for small tumors (<2cm), detailed T/N staging, and FNA biopsy.
• Biopsy: EUS-FNA preferred for histological proof, esp. for neoadjuvant therapy or unresectable cases.
• Staging: AJCC TNM. Defines Resectable, Borderline Resectable, Unresectable disease.

⭐ Courvoisier's Law: Palpable, non-tender gallbladder + jaundice → suspect malignancy (e.g., pancreatic head), not just stones.

Management - Pancreas Combat Plan

• Core Strategy: Multimodal approach: Surgery, Chemotherapy (Neoadjuvant/Adjuvant/Palliative), ± Radiotherapy (RT). Goal: R0 resection.
• Treatment based on Resectability:
  • Resectable:
    • Surgery: Pancreaticoduodenectomy (Whipple) for head; Distal pancreatectomy ± splenectomy for body/tail.
    • Adjuvant Chemo: $mFOLFIRINOX$ or $Gemcitabine + Capecitabine\ (GemCap)$. Duration: 6 months.
  • Borderline Resectable:
    • Neoadjuvant Therapy (Chemo ± RT) to downstage.
    • Regimens: $FOLFIRINOX$, $Gemcitabine + Nab-Paclitaxel$.
    • Re-assess for surgery.
  • Locally Advanced/Unresectable (No Mets):
    • Definitive Chemoradiation or Palliative Systemic Chemotherapy.
  • Metastatic:
    • Palliative Systemic Chemotherapy: $FOLFIRINOX$ ($FOLinic\ acid + Fluorouracil + IRINotecan + OXaliplatin$) or $Gemcitabine + Nab-Paclitaxel$.
    • Best supportive care.

• Palliative Interventions: Endoscopic stenting (biliary/duodenal obstruction), celiac plexus neurolysis (pain), nutritional support.

⭐ For resectable pancreatic cancer, adjuvant chemotherapy with mFOLFIRINOX offers improved survival over gemcitabine monotherapy compared to older regimens or observation alone after surgery (PRODIGE 24 trial).

High‑Yield Points - ⚡ Biggest Takeaways

• Ductal adenocarcinoma is the most common type, primarily in the pancreatic head.
• Painless, progressive jaundice is a classic sign for head tumors; Courvoisier's law may be present.
• CA 19-9 is the primary tumor marker, used for monitoring.
• Smoking is the strongest modifiable risk factor.
• Whipple procedure (pancreaticoduodenectomy) is the standard surgery for resectable head lesions.
• Overall prognosis is poor due to late presentation and aggressive nature.
• Common genetic mutation: KRAS (>90%).